|
|
Profile
|
Delegates :
Shin Hatou |
|
Incorporated :
June 20 , 2025 |
Paid in Capital :
29 Million yen |
Employees :
5 人 |
Address :
Ginza Ootake Bizidence 2F, 1-22-11 Ginza, Chuo-ku TOKYO
〒104-0061
|
TEL/FAX :
/ |
URL：
https://caksusbio.com/ |
Attachment :
|
Mission/Background :
Caksus Bio Inc. is a regenerative medicine startup originating from Keio University. The company develops regenerative medicine products based on iPSC-derived corneal endothelial substitute cells for the treatment of bullous keratopathy. Its mission is to overcome donor shortages and limitations of conventional corneal transplantation through innovative cell therapy technologies, expanding access to treatment for patients worldwide. |
|
Technology & Business
|
Caksus Bio develops proprietary technologies for the efficient differentiation and large-scale production of corneal endothelial substitute cells from induced pluripotent stem cells (iPSCs). Its cell injection therapy aims to restore corneal endothelial function without requiring donor corneas, potentially reducing surgical complexity and improving patient access to treatment. The company is also advancing manufacturing, quality control, and commercialization capabilities for regenerative medicine products.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
CLS001A
|
Preclinical
|
Allo-iPSC derived corneal endothelial substitute cell therapy
|
Advance clinical development and IND-enabling studies
|
CLS001U
|
Discovery
|
Auto-iPSC derived corneal endothelial substitute cell therapy
|
Technical Improvements
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Caksus Bio was established in 2025 and succeeded the CLS001A business from Cellusion, including intellectual property, manufacturing know-how, development data, and related agreements. The company is building a development platform for corneal endothelial regenerative medicine with global commercialization potential.
|
|
Hot news
|
Caksus Bio is accelerating development of CLS001A, an iPSC-derived corneal endothelial cell therapy acquired from Cellusion, aiming to provide a scalable alternative to corneal transplantation and expand access to advanced regenerative medicine worldwide.
|
|
Alliance strategy
|
The company seeks partners for collaborative research, technology licensing, clinical development, manufacturing, and global commercialization of regenerative medicine products based on iPSC technologies. Caksus Bio welcomes opportunities for strategic partnerships in Japan and overseas.
|
|
|